Phys Clinical Cases · rheumatological
Drug Induced Rheumatological Disease AND Biologics Safety — DCE Clinical Case
DCE long-case and short-case station for Drug Induced Rheumatological Disease AND Biologics Safety.
On this page & tools
Target exams
Drug Induced Rheumatological Disease AND Biologics Safety — Clinical Case
DCE Long Case
Patient brief
Patient: A middle-aged or older adult with multimorbidity and a presentation centred on Drug Induced Rheumatological Disease AND Biologics Safety. [1]
Presenting complaint: Subacute or acute symptoms referable to Drug Induced Rheumatological Disease AND Biologics Safety, with enough detail to force prioritisation. [1] [2]
Past history: Common cardiometabolic and organ comorbidities that interact with the plan. [2]
Medications: A polypharmacy list that includes at least one interaction or dosing issue. [2]
Examination: Key positives and critical negatives for dangerous differentials. [1]
Investigations: A small set of results that change management. [1] [2]
Tasks
- Present a prioritised problem list. [1]
- Defend investigations and immediate therapy. [1] [2]
- Provide safety-net and follow-up advice. [2]
Model discussion points
- Working diagnosis and acuity. [1]
- Differentials and discriminators. [2]
- Treatment sequence and monitoring. [1] [2] [3]
- Multimorbidity and communication. [2]
Short case
Focused examination or counselling station linked to Drug Induced Rheumatological Disease AND Biologics Safety, with one interpretation task and one shared-decision point. [1] [2]
References
- [1]Pandey SN, Babu MA, Goyal K, Menon SV, et al. Targeting NLRP3 inflammasome with curcumin: mechanisms and therapeutic promise in chronic inflammation Inflammopharmacology, 2025.PMID 40928616
- [2]Dans-Caballero S, Cecchi I, Radin M, Sciascia S JAK inhibitors for the management of rheumatic diseases when antiphospholipid syndrome co-exists: case-based safety considerations Lupus, 2025.PMID 40393677
- [3]Sciascia S, Foddai SG, Arbrile M, Radin M, et al. Assessing the steroid-sparing effect of biological agents in randomized controlled trials for lupus: a scoping review Immunol Res, 2024.PMID 38459403
- [4]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [5]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922
- [6]Hajiaqaei M, Mohammadi A Transcranial random noise stimulation (tRNS) over the left dorsolateral prefrontal cortex ameliorates emotion dysregulation and executive function: a single-blind, randomized, sham-controlled clinical trial BMC Psychol, 2026.PMID 42469906
- [7]D'Gama JD, Bermas BL Safety of biologic agents for the management of rheumatic diseases during pregnancy Curr Opin Rheumatol, 2024.PMID 38456470
- [8]Sánchez-García V, Hernández-Quiles R, de-Miguel-Balsa E, Giménez-Richarte Á, et al. Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta-analysis J Eur Acad Dermatol Venereol, 2023.PMID 37262303